G Ianiro1, L Masucci2, G Quaranta2, C Simonelli1, L R Lopetuso1, M Sanguinetti2, A Gasbarrini1, G Cammarota1. 1. Internal Medicine, Gastroenterology and Liver Unit, Gastroenterology and Oncology Area, Fondazione Policlinico Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy. 2. Institute of Microbiology, Fondazione Policlinico Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy.
Abstract
BACKGROUND:Faecal microbiota transplantation (FMT) is a highly effective treatment against recurrent Clostridium difficile infection. Far less evidence exists on the efficacy of FMT in treating severe Clostridium difficile infection refractory to antibiotics. AIM: To compare the efficacy of two FMT-based protocols associated with vancomycin in curing subjects with severe Clostridium difficile infection refractory to antibiotics. METHODS:Subjects with severe Clostridium difficile infection refractory to antibiotics were randomly assigned to one of the two following treatment arms: (1) FMT-S, including a single faecal infusion via colonoscopy followed by a 14-day vancomycin course, (2) FMT-M, including multiple faecal infusions plus a 14-day vancomycin course. In the FMT-M group, all subjects received at least two infusions, while those with pseudomembranous colitis underwent further infusions until the disappearance of pseudomembranes. The primary outcome was the cure of refractory severe Clostridium difficile infection. RESULTS:Fifty six subjects, 28 in each treatment arm, were enrolled. Twenty one patients in the FMT-S group and 28 patients in the FMT-M group were cured (75% vs 100%, respectively, both in per protocol and intention-to-treat analyses; P = 0.01). No serious adverse events associated with any of the two treatment protocols were observed. CONCLUSIONS: A pseudomembrane-driven FMT protocol consisting of multiple faecal infusions and concomitant vancomycin was significantly more effective than a single faecal transplant followed by vancomycin in curing severe Clostridium difficile infection refractory to antibiotics. Clinical-Trials.gov registration number: NCT03427229.
RCT Entities:
BACKGROUND: Faecal microbiota transplantation (FMT) is a highly effective treatment against recurrent Clostridium difficileinfection. Far less evidence exists on the efficacy of FMT in treating severe Clostridium difficileinfection refractory to antibiotics. AIM: To compare the efficacy of two FMT-based protocols associated with vancomycin in curing subjects with severe Clostridium difficileinfection refractory to antibiotics. METHODS: Subjects with severe Clostridium difficileinfection refractory to antibiotics were randomly assigned to one of the two following treatment arms: (1) FMT-S, including a single faecal infusion via colonoscopy followed by a 14-day vancomycin course, (2) FMT-M, including multiple faecal infusions plus a 14-day vancomycin course. In the FMT-M group, all subjects received at least two infusions, while those with pseudomembranous colitis underwent further infusions until the disappearance of pseudomembranes. The primary outcome was the cure of refractory severe Clostridium difficileinfection. RESULTS: Fifty six subjects, 28 in each treatment arm, were enrolled. Twenty one patients in the FMT-S group and 28 patients in the FMT-M group were cured (75% vs 100%, respectively, both in per protocol and intention-to-treat analyses; P = 0.01). No serious adverse events associated with any of the two treatment protocols were observed. CONCLUSIONS: A pseudomembrane-driven FMT protocol consisting of multiple faecal infusions and concomitant vancomycin was significantly more effective than a single faecal transplant followed by vancomycin in curing severe Clostridium difficileinfection refractory to antibiotics. Clinical-Trials.gov registration number: NCT03427229.
Authors: Massimo Antonelli; Ignacio Martin-Loeches; George Dimopoulos; Antonio Gasbarrini; Maria Sole Vallecoccia Journal: Intensive Care Med Date: 2020-01-14 Impact factor: 17.440
Authors: Theodore Rokkas; Javier P Gisbert; Antonio Gasbarrini; Georgina L Hold; Herbert Tilg; Peter Malfertheiner; Francis Megraud; Colm O'Morain Journal: United European Gastroenterol J Date: 2019-05-27 Impact factor: 4.623
Authors: Emily N Tixier; Elijah Verheyen; Yuying Luo; Lauren Tal Grinspan; Charles H Du; Ryan C Ungaro; Samantha Walsh; Ari M Grinspan Journal: Dig Dis Sci Date: 2021-03-22 Impact factor: 3.199